Cargando…
Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease
PURPOSE: Autosomal recessive polycystic kidney disease (ARPKD) is a hereditary condition characterized by massive kidney enlargement and developmental liver defects. Potential consequences during childhood include the need for kidney replacement therapy (KRT). We report the design of 2 ongoing clini...
Autores principales: | Mekahli, Djalila, Liebau, Max C., Cadnapaphornchai, Melissa A., Goldstein, Stuart L., Greenbaum, Larry A., Litwin, Mieczyslaw, Seeman, Tomas, Schaefer, Franz, Guay-Woodford, Lisa M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926647/ https://www.ncbi.nlm.nih.gov/pubmed/36782137 http://dx.doi.org/10.1186/s12882-023-03072-x |
Ejemplares similares
-
Gastrostomy Tube Insertion in Pediatric Patients With Autosomal Recessive Polycystic Kidney Disease (ARPKD): Current Practice
por: Burgmaier, Kathrin, et al.
Publicado: (2018) -
Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial
por: Schaefer, Franz, et al.
Publicado: (2019) -
Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspective
por: De Rechter, Stéphanie, et al.
Publicado: (2018) -
Recent Progress of the ARegPKD Registry Study on Autosomal Recessive Polycystic Kidney Disease
por: Ebner, Kathrin, et al.
Publicado: (2017) -
Translational research approaches to study pediatric polycystic kidney disease
por: Liebau, Max Christoph, et al.
Publicado: (2021)